Fig. 6From: Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistanceCircRNAs affect m6A modification in cancer therapeutic resistance. CircRNAs modulate the expression of or interact with m6A regulators, thereby influencing m6A functions in multiple cancers. (1) In glioma: circ_0072083 promoted ALKBH5 expression, leading to temozolomide resistance. (2) In CRC: circPTK2 elevated YTHDF1 level, resulting in 5-FU and oxaliplatin resistance. (3) In HCC: circRHBDD1 recruited YTHDF1, leading to anti-PD-1 therapy resistance. (4) In BC: circ0008399 facilitated the formation of MTC through combining with WTAP, thereby elevating cisplatin resistance. Furthermore, circMORC3 promoted cisplatin resistance by interacting with VIRMA. (5) In prostate cancer: circARHGAP29 interacted with IGF2BP2, thus augmenting docetaxel resistanceBack to article page